Did Northwest Biotherapeutics Just Check Off 1 Box Needed for Its Stock to Double?
In April, Northwest Biotherapeutics (OTC: NWBO) disclosed that its phase 3 clinical trial to evaluate its cancer immunotherapy vaccine DCVax-L in treating glioblastoma, the most invasive form of brain cancer, may finally be coming to an end. The company believes it will reach the required number of death events in for its primary endpoint of overall survival for the trial to conclude by the end of May. It estimates that it will be able to publicly announce top-line data by June to early July.
Well, this is good news because investors have been waiting for 14 years for that announcement. Does the company's tumor vaccine possess the potential to tackle a multibillion-dollar market opportunity? Let's go ahead and find out.
Image source: Getty Images.
Source Fool.com
